GlaxoSmithKline pharmaceuticals news

The U.S. Court of Appeals for the Federal Circuit agreed to stay GSK's suit against the U.S. Patent and Trademark Office until 60 days after the Senate confirms a new undersecretary of commerce for intellectual property and director of the USPTO. As a result, oral arguments originally scheduled for Oct. 7 will be delayed. The CAFC recently agreed to rehear the suit, which concerns the agency's final rules concerning patent applications. (see BioCentury, July 13). ...